Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers at University of Bonn have published new data on cancer vaccines
July 7th, 2009
According to recent research from Bonn, Germany, "Immune-mediated tumor rejection relies on fully functional T-cell responses and neutralization of an adverse tumor microenvironment. In clinical trials, we detected peptide-specific but non-tumor-reactive and therefore not fully functional CD8(+) T cells post-vaccination against tumor antigens." "Understanding the molecular mechanisms behind nontumor reactivity will he a prerequisite to overcome this CD8(+) T-cell deviation. We report that these non-tumorreactive CD8(+) T cells are characterized by a molecular program associated with hallmarks of ''division arrest anergy.'' Non-tumor-reactive CD8(+) T cells are...
Source: Cancer Weekly (2009-07-07)
|
